Abin da Yarjejeniyar ImmuPharma ke Bayyana Game da Dabarun Peptide CMC

Ƙirƙirar Tsarin ImmuPharma's Tripartite CMC

Littafin wasan kwaikwayo na gargajiya na waje ya ƙarfafa fasahar biotechs don haɗa shirye-shiryen farko-farko a ƙarƙashin mai siyarwa na farko don sauƙaƙe sarrafa kwangila. Duk da haka, yayin da peptide therapeutics suka zama mafi rikitarwa a cikin sinadarai - suna buƙatar musanyawan amino acid waɗanda ba na halitta ba., hadaddun hawan keke, da ingantacciyar ingancin nazarin halittu-samfurin tushen tushe guda ɗaya sau da yawa yakan ci karo da ƙullun aiki.

Dabarar ImmuPharma don Kapiglucagon (A peptide analog niyya Type 1 ciwon sukari da kuma tsananin hypoglycemia ta hanyar U.S. 505(b)(2) hanyar tsari) ya warware manyan fannoni guda uku:

1. Sinadarin Magunguna Mai Aiki (API) Magana: An samo asali daga ƙwararren shugaban chemistry peptide mai ikon sarrafa hadadden peptide hadaddun lokaci mai ƙarfi. (SPSS) da tsarkakewa.

   

2. Samfurin Magunguna (DP) & Cika-Kammala Kasuwanci: Haɗin gwiwa tare da CDMO na Tier-1 na duniya mai mallakar manyan masana'anta bakararre, cika vial, da kayan aikin sanyi-sarkar.

3. Peptide Synthesis Tsarin Halittun Halitta: An sanya shi zuwa GLP-certified, GCP-mai yarda, da ƙungiyar binciken kwangilar da FDA ta bincika (CRO) don haɓaka kai tsaye da inganta hanyoyin bioanalytical don marasa aikin likita da lokaci 1 samfurori na asibiti.

Key Takeaway: Unbundling API sunadarai, cika samfurin magani, da tsarin nazarin halittu na tsari yana hana ƙulla iyawar mai siyarwa guda ɗaya yayin da tabbatar da cewa ingancin tantancewa ya kasance na haƙiƙa kuma a shirye yake..

Wannan rabe-raben aiki yana magance ainihin gaskiya a cikin ci gaban magungunan peptide: ƙwarewar fasaha da ake buƙata don haɓaka haɗin peptide mai tsafta ya bambanta sosai da waɗanda ake buƙata don cikawa bakararre ko nazarin halittu na asibiti..

Monolith Paradox: Me yasa CDMOs Tsaya Daya Tsaya Karkashin Rukunin Peptides

Manyan CDMO na duniya sun tallata samfuran sabis na "ƙarshe-zuwa-ƙarshe" waɗanda ke yin alƙawarin gudanar da ayyukan haɗin gwiwa tare da rage ɓangarorin hannu.. A aikace, duk da haka, masu tallafawa biopharma da ke aiki akan ƙwararrun ƴan takarar peptide akai-akai suna saduwa da wuraren jujjuyawar tsari guda uku a cikin wuraren monolithic.:

1. Matsalolin Ƙarfafa fifiko

Haɓakawa na duniya a cikin masu karɓar masu karɓa na GLP-1 na kasuwanci sun cinye babban ƙarfin CDMO. Manyan cibiyoyin sadarwar masana'antu suna ba da fifiko ta dabi'a Peptides na roba batches na kasuwanci masu girma sama da farkon-zuwa-tsakiyar gudu na asibiti, yana haifar da jinkirta jinkiri don shirye-shiryen peptide na musamman.

2. Rashin sassaucin ra'ayi na Fasaha don Kimiya na Bespoke

Daidaitaccen layukan samar da CDMO an ƙirƙira su don babban aiki, maimaita matakai. Lokacin da jerin peptide ya gabatar da haɗuwar hydrophobic mai tsanani, disulfide mai wahala, ko yana buƙatar gyare-gyaren ayyuka na musamman, manyan CDMOs na iya rasa ƙarfi ko shirye don yin sauri, warware matsalar kira na maimaitawa.

3. Hatsarin Nazari na Binciken Kai

Lokacin da mahaɗin ɗaya ke haɗa API, yana tsara samfurin magani, kuma yana tabbatar da hanyoyin sakin nazari, rikice-rikice na cikin gida na iya tasowa. Tabbacin CRO mai zaman kansa yana ba da hukumomin gudanarwa tare da tabbacin tsafta marar son rai, kwanciyar hankali, da rashin tsarki.

Binciken masana'antu game da ƙwararrun gine-ginen CDMO da yawa da rarraba haɗari nuna cewa rarraba alhakin fasaha a tsakanin ƙwararrun abokan hulɗa yana ba da damar fasahar kere-kere don kula da sarrafa manyan abubuwan ci gaba yayin samun ƙwarewar manyan matakai a kowane kullin ci gaba..

Matrix Tsarin Tsare-tsare: Mahalli na Multi-Partner vs. Tushen CDMO guda ɗaya

Don sanin ko dabarun abokan hulɗa da yawa da ba a haɗa su ba ko tushen CDMO guda ɗaya ya fi dacewa da takamaiman bututun peptide., Shugabancin biopharma ya kamata ya kimanta shirye-shiryen ta fuskoki huɗu na aiki:

Matsayin Kwararru na Nimble Peptide a cikin Tsarin Muhalli na CMC

Yayin da CDMOs Tier-1 ke ba da mahimman abubuwan more rayuwa don samar da samfuran magunguna na ƙarshen zamani, inganta matakin farko, zaɓin ɗan takara, kuma gyare-gyaren sinadarai na buƙatar wani sawun aiki daban.

Wannan shi ne inda na musamman, Agile peptide dandamali suna taka muhimmiyar rawa. Maimakon yin gasa kai tsaye tare da kattai na cika-kasuwa na kasuwanci, Masu samar da peptide masu nimble suna aiki azaman ingin haɗakarwa na cibiyar sadarwar abokan tarayya da yawa.

Misali, lokacin da ƙungiyoyin binciken biopharma ke buƙatar ƙira na al'ada, hadaddun hawan keke, ko gyare-gyaren ƙungiyar aiki, aiki da na musamman peptide kira da gyare-gyare dandamali yana ba da damar haɓakar fasaha cikin sauri wanda CDMO na monolithic ba zai iya daidaitawa ba.

Bench R&D / Inganta jagora

ƙwararren Peptide Nimble • Haɗin jerin al'ada (>300 gyare-gyare) • Class 100 Haɗuwar ɗaki mai tsaftar bakararre • Halayen tsafta mai girma (HPLC ≥95-98%+, MS, CoA) ▼ (Tsaftace Hannun Nazari) Tier-1 Cika-Gama CDMO Independent Bioanalytical CRO • Bakararre DP masana'antu • Ingantacciyar hanyar tsari • Cika vial na ƙarshe • Mara asibiti. / Mataki 1 gwaji

Mabuɗin gudummawar aiki na ƙwararrun dillalan peptide sun haɗa da:

• Canje-canjen Magana a Sikeli: Ƙaddamar da ƙare 300 gyare-gyaren ƙungiyar aiki-kamar phosphorylation, fluorophore tagging, barga isotope lakabin, da shigar da amino acid marasa dabi'a - ba tare da buƙatar babban ƙarami ba.

• Kare Muhalli na Bakararre: Amfani da Class 100 Mahalli mai tsabta mai tsabta mai tsabta a lokacin shiri na farko yana tabbatar da ƙarancin endotoxin da matakan ɓarna, kare bayanan tushen tantanin halitta da farkon binciken vivo daga abubuwan gurɓatawa.

• Gada mara kyau: Samar da masana'antar peptide na al'ada mai ƙima wanda ke haɗa farkon matakin-miligram nunawa zuwa ƙimar gram-da-kilogram yana ba ƙungiyoyin biopharma damar inganta hanyoyin roba kafin canja wurin matakai zuwa wuraren samar da kasuwanci..

Kisa Aiki: Ka'idoji don Rarraba Hannun Hannun Nazari

Haɗarin farko na yanayin mahalli na abokin tarayya na CMC shine jujjuyawar mu'amala yayin aikin hannu na fasaha. Don aiwatar da samfurin mai raba-gari cikin nasara, ƙungiyoyin biopharma CMC yakamata su aiwatar da kariyar aiki guda huɗu:

1. Kafa Ka'idojin Canja wurin Nazari masu jituwa

Kafin fara haɗin API, daidaita mai siyar API, Bioanalytical CRO, da DP CDMO akan chromatography Liquid High Performance Reverse-Phase iri ɗaya. (Farashin RP-HPLC) da Liquid Chromatography-Mass Spectrometry (LC-MS) ginshiƙan sunadarai, wayoyin hannu, da sigogin ganowa.

2. Daidaita Takaddun Takaddun Bincike (CoA) Bukatun Kunshin Bayanai

Bukatar duk dillalai masu shiga don samar da daidaitaccen ɗanyen chromatograms, taro bakan, eantiomeric tsarki awo, da sauran sauran ƙarfi bincike. Fassara a cikin bayanan batch yana hana bambance-bambance lokacin tara Module 3 Takardar bayanan IND.

3. Aiwatar da Ƙuntataccen Endotoxin da Iyakar Haihuwa

Ƙayyade madaidaitan matakan endotoxin lokaci-lokaci (misali, <0.1 EU/mg don ƙayyadaddun tsari) a matakin API. Tabbatar da cewa mai ba da haɗin API yana kiyaye tsayayyen kulawar muhalli yana hana ƙin yarda da samfuran magunguna a ƙasa yayin kammala cikawar bakararre..

4. Gina Tsarin Mulki na RACI Uku Uku

A fayyace Alhaki a sarari, Mai lissafi, An shawarci, da Sanarwa ayyuka a duk ƙungiyoyin masu siyarwa guda uku. Zaɓar jagoran aikin CMC na cikin gida don zama tushen gaskiya guda ɗaya don sa hannu kan yarjejeniya da ƙaddamarwa na tsari..

Don Tukwici: Gudanar da taron daidaita daidaiton haɗin gwiwa tare da wakilai daga API synthesizer, Bioanalytical CRO, da cika CDMO kafin kammala ƙayyadaddun kwangila. Haɓaka tsammanin nazari da wuri yana kawar da sake sake tabbatarwa masu tsada.

Gina Tsarin Gine-gine na Peptide CMC

An tura ImmuPharma na Kymos Group, Thermo Fisher Scientific, kuma Bachem ya nuna cewa haɓaka magungunan peptide na zamani baya buƙatar masu tallafawa biopharma don zaɓar tsakanin kulle mai siyarwa ko gabaɗayan aikin aiki..

Ta hanyar haɗa tsarin yanayin yanayin CMC na zamani, Shugabannin biopharma na iya yin amfani da manyan CDMOs don sikelin, CROs masu zaman kansu don nazarin halittu marasa son rai, da ƙwararrun peptide masu nimble don haɗakar sinadarai masu wahala da saurin gyarawa.

Don daraktocin bincike da injiniyoyi masu aiki suna kimanta bututun peptide masu zuwa, duba dabarun ku na CMC na yanzu akan waɗannan tambayoyin:

• Shin abokin tarayya na API sanye take don gudanar da gyare-gyare masu rikitarwa ba tare da gabatar da jinkirin layin ba?

• Shin hanyoyin sakin ku na nazari sun inganta ba tare da kera na'urar tantance kai ba?

• Kuna da ƙayyadaddun ƙa'idar canja wurin fasaha mai haɗa farkon haɗin benci zuwa layin kammala kasuwanci?

Yin kimanta waɗannan sigogi da wuri yana ba ƙungiyoyin biopharma damar damfara lokutan ci gaba, kula da sassaucin fasaha, da kuma gabatar da hukumomin gudanarwa tare da cikakkiyar ɓarna, masu ƙarfi CMC dossier.

Game da Marubuta

An haɗa wannan tsarin aiki na dabarun aiki ta hanyar MOL Canje-canje a Kimiyya & Ƙungiyar Shawarar CMC. Canje-canje na MOL ƙwararre ce ta bincike da ƙungiyar ci gaba wanda ke haɗa zurfin gwaninta a cikin sinadarai na halitta, peptide kira, da halayen halitta. Ƙungiyar ta ƙware a ƙirar peptide na al'ada, hadaddun gyare-gyaren aiki (>300 ƙungiyoyin aiki), da samar da tsabta mai tsabta a ƙarƙashin Class 100 yanayin ɗaki mai tsafta mara kyau, tallafawa masu binciken ilimi, masu haɓaka biopharma, da abokan aikin masana'antu a duniya.